Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-12

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, which will be performed as a randomized clinical trial, all patients with macular edema with central involvement (central macular thickness greater than 300 μm) and corrected vision less than or equal to 20/40 and better than 20/400 were included in the study. After a thorough eye examination, people are randomly divided into two groups. The first group was treated with intravitreal injection of Bevacizumab in three injections one month apart with receiving oral Acetazolamide tablets of 250 mg twice a day, and the second group was treated with intravitreal injection of Bevacizumab for three Loads are spaced one month apart. Ophthalmologic examinations and corrected visual acuity, as well as macular thickness examination, are repeated with Spectral-domain Optical coherence tomography (SD-OCT) at the beginning of treatment and at the end of the first, second, and third months. At the end of the study, the rate of changes in visual acuity and macular thickness in the eyes in the two groups will be compared and will be statistically analyzed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial

NCT00370422

Diabetic Macular Edema

UNKNOWN PHASE3

Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients

NCT03391219

Retinal Vein Occlusion

UNKNOWN PHASE2/PHASE3

Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema

NCT00370669

Diabetic Macular Edema

UNKNOWN PHASE3

Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema

NCT01823081

Diabetic Macular Edema

COMPLETED PHASE3

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

NCT04812977

Central Retinal Vein Occlusion With Macular Edema

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

investigate of the effect of intravitreal injection of bevacizumab with acetazolamide tablets

Group Type ACTIVE_COMPARATOR

intravitreal injection of bevacizumab with acetazolamide tablets

Intervention Type DRUG

intravitreal injection of bevacizumab with acetazolamide tablets

Investigate the effect of intravitreal injection of bevacizumab alone

Group Type ACTIVE_COMPARATOR

intravitreal injection of bevacizumab

Intervention Type DRUG

intravitreal injection of bevacizumab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravitreal injection of bevacizumab with acetazolamide tablets

Intervention Type DRUG

intravitreal injection of bevacizumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 20 / 400≤ Best Corrected Visual Acuity ≤20 / 40
* Central macular thickness \<300 μm
* The onset of the disease is less than three years
* No other eye diseases that affect the evaluation and process of this study.

Exclusion Criteria

* It is not possible to provide informed consent.
* Patients who are prohibited from taking oral acetazolamide (renal failure, hepatic failure, history of allergies)
* Other eye diseases that affect the evaluation and process of this study. Including diabetes retinopathy
* History of retinal laser photocoagulation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes